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Background: Cystatin D is a cysteine protease inhibitor with tumor suppressor action.
Results: A proportion of cystatin D protein localizes within the cell nucleus at specific active chromatin sites and regulates gene
transcription.
Conclusion: Cystatin D is a multifunctional protein with protease inhibitory and gene regulatory activities.
Significance: Regulation of cystatin D in colon cancer cells has phenotypic consequences beyond the inhibition of lysosomal and
secreted cysteine proteases.
Cystatin D is an inhibitor of lysosomal and secreted cysteine
proteases. Strikingly, cystatin D has been found to inhibit pro-
liferation, migration, and invasion of colon carcinoma cells indi-
cating tumor suppressor activity that is unrelated to protease
inhibition. Here, we demonstrate that a proportion of cystatin D
locates within the cell nucleus at specific transcriptionally active
chromatin sites. Consistently, transcriptomic analysis show that
cystatin D alters gene expression, including that of genes encod-
ing transcription factors such as RUNX1, RUNX2, and MEF2C in
HCT116 cells. In concordance with transcriptomic data, quan-
titative proteomic analysis identified 292 proteins differentially
expressed in cystatin D-expressing cells involved in cell adhe-
sion, cytoskeleton, and RNA synthesis and processing. Further-
more, using cytokine arrays we found that cystatin D reduces the
secretion of several protumor cytokines such as fibroblast
growth factor-4, CX3CL1/fractalkine, neurotrophin 4 oncosta-
tin-M, pulmonary and activation-regulated chemokine/CCL18,
and transforming growth factor B3. These results support an
unanticipated role of cystatin D in the cell nucleus, controlling
the transcription of specific genes involved in crucial cellular
functions, which may mediate its protective action in colon
cancer.
Cystatin D is a member of the cystatin superfamily of inhib-
itors of cathepsins, cysteine proteases that degrade multiple
targets including adhesion proteins, matrix components, and
other proteases (1, 2). Human cystatin D inhibits cathepsins H,
S, and L but not B; it was originally purified from saliva and is
encoded by the CST5 gene (3, 4). We have previously reported
that cystatin D promotes cell adhesion and decreases prolifer-
ation, migration, and invasion of colon carcinoma cells. It is
down-regulated during human colon carcinogenesis, and con-
sidered as a candidate tumor suppressor that is transcription-
ally induced by 1,25-(OH)2D3, the most active metabolite of
vitamin D, mediating its protective effects against this neoplasia
(5). The finding that mutant forms of cystatin D with no prote-
ase inhibitory activity lack the antimigratory but not the anti-
proliferative effect indicates that cystatin D has cathepsin-inde-
pendent mechanism(s) of action.
A number of cathepsins are thought to be involved in cancer
and other diseases as regulators of a variety of biochemical pro-
cesses (1, 2). Likewise, cystatins play multiple roles in physiol-
ogy and pathology, including tumorigenesis and neurodegen-
erative disorders (6). Preferential attention has been paid to the
deregulation and imbalance between cathepsins and cystatins
in invasion and metastasis of several neoplasias (6 –10). Cathe-
psins have traditionally been considered endosomal/lysosomal
or secreted proteases; however, new evidence supports their
localization in other cellular compartments. Recent studies
have reported the activity of cathepsin L, a cystatin D target,
within the cell nucleus (11–13). Analogously, a few cystatins
and other protease inhibitors have been found to act in the
nuclear compartment (14 –16).
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Taken together, these findings prompted us to investigate in
depth the mechanism of action of cystatin D protein in colon
carcinoma cells. In this study, we demonstrate that a propor-
tion of endogenous and exogenous cystatin D is nuclear and
co-localizes with histone markers of active chromatin such as
H3K36me3 and RNA polymerase II at specific sites of active
transcription. Transcriptomic and proteomic analyses identi-
fied a number of cancer-related genes whose expression at the
RNA and/or protein level is altered by cystatin D. These results
reveal a novel biological activity of cystatin D as a modulator of
gene expression that is related to an unpredicted nuclear local-
ization, and explains its tumor suppressor activity mediating
vitamin D action in colon cancer.
Experimental Procedures
Cell Culture—Human SW480-ADH and HCT116 colon ade-
nocarcinoma cell lines were maintained in Dulbecco’s modified
Eagle’s medium containing 10% fetal bovine serum and 2 mM
L-glutamine (all from Invitrogen, Paisley, UK). SW480-ADH
and HCT116 cells stably expressing cystatin D (SW480-ADH-
CST5, HCT116-CST5 clone 9 and clone 20) or mock-trans-
fected (SW480-ADH-Mock, HCT116-Mock) were generated
as described (5).
Gene Silencing—To knockdown CST5 expression HCT116
cells were infected with lentiviral particles containing a U6 pro-
moter driving a short hairpin RNA (shRNA) targeting CST5
RNA (Mission TRC shRNA; Sigma). Lentiviral particles against
human CST5 or scramble negative control were used. After
infection the cells were treated with 1 !g/!l of puromycin
(Sigma). In parallel, lentiviral particles codifying the TurboGFP
gene (clone SHC003; Sigma) were used to estimate transfection
efficiency. Control cells were infected with lentivirus bearing a
non-targeting shRNA that activates the RISC complex and the
RNA interference (RNAi) pathway but contains at least five
mismatched nucleotides compared with any human gene
(clone SHC002; Sigma).
Immunofluorescence and Confocal Microscopy—Cultured
cells were grown on 10 ! 10-mm glass coverslips. The cells
were washed twice in phosphate-buffered saline (PBS) and
fixed with 3.7% formaldehyde (freshly prepared from parafor-
maldehyde) in PBS for 15 min at room temperature. For the
immunodetection of the largest subunit of the RNA polymerase
II (H5 antibody) and histone H3K36me3, cells were fixed with
3.7% paraformaldehyde containing 0.5% Triton X-100 for 10
min. Following fixation, all cell samples were sequentially incu-
bated with 0.5% Triton X-100 in PBS for 30 min, 2% BSA in PBS
for 30 min, and 0.05% Tween 20 in PBS for 5 min. Cells were
then incubated for 2 h at room temperature with the primary
antibody diluted in PBS, washed in PBS containing 0.05%
Tween 20, incubated for 45 min with the appropriate secondary
antibodies conjugated with FITC or Texas Red (Jackson Immu-
noResearch Laboratories, West Grove, PA), and mounted with
VectaShield (Vector Laboratories, Peterborough, UK).
Confocal microscopy was performed with an LSM510 laser
scanning microscope (Carl Zeiss, Oberkochen, Germany) using
excitation wavelengths of 488 (for FITC) and 543 nm (for Texas
Red). All confocal scans were acquired with the LSM510 soft-
ware using a Plan Apochromat !63 NA 1.4 objective (Carl
Zeiss). Images were collected with 8-fold averaging at 1024 !
1024 pixel resolution using pinhole settings between 0.9 and 1
airy units. For double labeling experiments, images of the same
confocal plane were sequentially recorded and pseudocolor
images were generated and superimposed. TIFF images were
further processed using Photoshop (CS3, Adobe Systems, San
Jose, CA) for presentation.
The following primary antibodies were used: goat polyclonal
anti-cystatin D antibody (N-19; blocking peptide (N-19)P,
Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal
anti-histone H3K36me3 (1:200, Upstate, New York, NY),
mouse monoclonal anti-pan-Histone (H11– 4, 1:200, Roche
Applied Science, Mannheim, Germany), mouse monoclonal
anti-2,2,7-trimethylguanosine cap (TMG-cap), which recog-
nizes the 5" cap structure of spliceosomal snRNPs (K121, 1:100,
Oncogene Research, La Jolla, CA), mouse monoclonal anti-
fibrillarin (38F3, 1:100, Abcam, Cambridge, UK), and mouse
monoclonal anti-RNA polymerase II, which recognizes the
largest subunit (Rpb1) phosphorylated on Ser2 of the heptapep-
tide repeat (H5 IgM antibody, 1:100, Covance, Princeton, NJ).
RNA Extraction, Real-Time PCR, and RT-PCR—Total
RNA from cultured cell lines was extracted using the Nucle-
oSpin" miRNA extraction kit (Macherey-Nagel, Duren,
Germany). Quantitative real-time (qRT)7-PCR (qRT-PCR)
analyses of CST5 (Hs00983867_m1), MAL2 (Hs00294541_
m1), MEF2C (Hs00231149_m1), AP1M2 (Hs00194014_
m1), RUNX2 (Hs00231692_m1), ID3 (Hs00171409_m1),
NAV3 (Hs00372108_m1), NT5E (Hs01573922_m1), VCAN
(Hs00171642_m1), WNT16 (Hs00365138_m1), ANX3
(Hs00192982_m1), RUNX1 (Hs01021970_m1), and EMP3
(Hs01011451_m1) were performed using the TaqMan Gene
Expression Master Mix (Thermo Fisher Scientific, Waltham,
MA). Thermal cycling was initiated with a denaturation step of
95 °C for 10 min and consisted of 40 cycles (denaturation at
95 °C 10 s, annealing and elongation at 60 °C for 60 s). RNA
expression values were normalized versus the housekeeping
18S and RPLPO rRNA. The reaction was performed in a
CFX384 Real-time PCR Detection System (Bio-Rad).
Cell Fractioning—To obtain nuclear extracts, cell monolay-
ers were washed in PBS and lysed for 15 min in hypotonic buffer
(10 mM HEPES, pH 7.5, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA) supplemented with 1 mM DDT, 1 mM orthovanadate, 1
mM PMSF, 10 !g/ml of leupeptin, and 10 !g/ml of aprotinin.
Just before centrifugation (15,700 ! g at 4 °C for 1 min), 10%
Nonidet P-40 was added to the tubes. Supernatants (cytosolic
extracts) were conserved at #80 °C until analysis. Pellets con-
taining nuclei were lysed by incubation for 30 min in hypertonic
buffer (20 mM HEPES, pH 7.5, 0.4 M NaCl, 1 mM EDTA, 1 mM
EGTA) supplemented as above, and then centrifuged at
15,700 ! g for 10 min at 4 °C. Supernatants (nuclear extracts)
were conserved at #80 °C until analysis.
Western Blotting—Western blot analysis was done as previ-
ously described (5). We used rabbit polyclonal antibodies gen-
erated against RUNX1 (Abcam) and NR3C1 and CBP/CREBBP
(Santa Cruz Biotechnology); mouse monoclonal antibodies
7 The abbreviations used are: qRT, quantitative real-time; TMG, 2,2,7-trimeth-
ylguanosine; SILAC, stable isotope labeling with amino acids in cell culture.
Nuclear Action of Cystatin D
26534 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290 • NUMBER 44 • OCTOBER 30, 2015
 at Centro N
acional de Investigaciones O









against IQGAP2 (Merck Millipore, Billerica, MA), RUNX2
(Medical and Biological Laboratories, MBL, Woburn, MA), and
"-tubulin and HDAC1 (Santa Cruz Biotechnology); and goat
polyclonal antibodies against cystatin D, ZEB1, and lamin B
(Santa Cruz Biotechnology). Secondary antibodies used were
HPR-conjugated anti-rabbit IgG (H$L) (MP Biomedicals,
Santa Ana, CA), anti-mouse IgG (H$L) (Promega, Madison,
WI), and anti-rat IgG and anti-goat IgG (Santa Cruz
Biotechnology).
Immunoelectron Microscopy—For double immunogold elec-
tron microscopy detection of cystatin D and RNA pol II, cul-
tured SW480-ADH cells were fixed with 4% paraformaldehyde
and 0.1% glutaraldehyde in 0.1 M cacodilate buffer for 30 min at
room temperature. After fixation, cells were scraped off, trans-
ferred to an Eppendorf tube, and centrifuged for 10 min at
13,400 ! g in a minicentrifuge. Cell pellets were washed in 0.1 M
cacodylate buffer, dehydrated in increasing concentrations of
methanol at #20 °C, embedded in Lowicryl K4M at #20 °C,
and polymerized by ultraviolet irradiation. Ultrathin sections of
60 nm were obtained by using an ultramicrotome (Ultracut
UCT, Leica), mounted on nickel grids and sequentially incu-
bated with 0.1 M glycine in PBS for 15 min, 5% BSA in PBS for 30
min and a goat polyclonal anti-cystatin D antibody (diluted 1:25
in 50 mM Tris-HCl, pH 7.6, containing 1% BSA) overnight at
4 °C. Ultrathin sections were then incubated with a mouse
monoclonal anti-RNA pol II antibody (H5, IgM, diluted 1:50 in
50 mM Tris-HCl, pH 7.6, containing 1% BSA) for 2 h at room
temperature and then with the appropriate secondary antibod-
ies coupled to 10 or 15 nm gold particles (BioCell; diluted 1:50
in PBS containing 1% BSA). Following immunogold labeling,
the grids were stained with uranyl acetate and examined under
a JEOL EM201 electron microscope. As controls, ultrathin sec-
tions were treated as described above but omitting primary
antibodies.
Global Gene Expression Using High-density Microarrays—
Genome-wide expression was analyzed in the isolated samples
using the GeneChip Human Gene 1.0 ST Array (from
Affymetrix, Santa Clara, CA). This microarray includes 804,372
distinct oligonucleotide probes and maps into 19,213 unique
human gene loci (17). RNA isolation, labeling, and microarray
hybridization followed the manufacturer’s protocols for the
GeneChip platform by Affymetrix. Methods included synthesis
of first- and second-strand cDNAs, the purification of double-
stranded cDNA, synthesis of cRNA by in vitro transcription,
recovery and quantitation of biotin-labeled cRNA, fragmenta-
tion of this cRNA and subsequent hybridization to the microar-
ray slide, post-hybridization washings, and detection of the
hybridized cRNAs using a streptavidin-coupled fluorescent
dye. Hybridized Affymetrix arrays were scanned with an
Affymetrix Gene-Chip 3000 scanner. Image generation and
feature extraction were performed using Affymetrix GCOS
Software.
Bioinformatic Analysis—The Robust Microarray Analysis
algorithm was used for background correction, intra- and inter-
microarray normalization, and expression signal calculation
(18). The absolute expression signal for each gene was calcu-
lated for each microarray. The expression signal was calculated
using the CDF package called GeneMapper from GATExplorer
(genemapperhumangene1.0cdf; see website) (17), which maps
into an updated version of human genes, instead of using the
original probe set definition provided by Affymetrix. This map-
ping provides an improvement thanks to the re-annotation to
updated gene loci and removal of cross-hybridation noise (17).
It also allows us to operate from the beginning using gene iden-
tification (Ensembl IDs) instead of probe sets (Affymetrix IDs).
Mapping to genome version Ensembl v57 (assembly GRCh37)
was used for these analyses.
Significance analysis of microarray (19) was applied to calcu-
late significant differential expression and find the genes that
characterized the samples of each compared state. In this
method, permutations provide robust statistical inference of
the most significant genes and using a false discovery rate (20)
to adjust the raw p values to multiple testing. Because the dif-
ferences in the two sets of microarrays compared (i.e. two
treated samples versus two control samples) were small, we use
several cumulative criteria to allow the selection of the most
significant genes: (i) first, we set up an open cut-off of false
discovery rate %0.25 to select the list of the genes with best
adjusted p values (this step provided a preliminar set of 377
genes); (ii) second, we considered the individual raw p value of
each gene setting up another cut-off of %0.01; (iii) third, we
ranked the genes by their signal fold-change (log2 scale) calcu-
lated with significance analysis of microarray algorithm and
selected only the top ones with cut-offs of fold-change &1.5 for
overexpression and fold-change %0.65 for repression. This
protocol allows identifying a final set of 69 genes that suffered a
relevant expression change induced by cystatin D. Following
the identification of differentially expressed genes, the corre-
sponding matrix of signal-normalized expression values for all
the samples hybridized was analyzed using the HCLUST clus-
tering algorithm. This algorithm performs hierarchical cluster
analysis with complete linkage to find similarity between genes
based on their expression (Pearson correlation) along the sam-
ples analyzed. The algorithm classifies the genes in correlated
groups presenting similar expression profiles. All the bioinfor-
matic analyses were performed with the statistical program-
ming R, using some Bioconductor and GATExplorer packages
(17).
Proteomic Analysis—Sample preparation and in-gel diges-
tion. For metabolic labeling, HCT116-CST5 clone 9 and
HCT116-Mock cells were maintained in DMEM supplemented
with 10% dialyzed FBS (Invitrogen), 100 units/ml of penicillin/
streptomycin (Invitrogen) at 37 °C and 5% CO2, and lysine or
arginine in either light (12C6) or heavy forms (13C6) (Dundee
Cell products, Dundee, ANS, United Kingdom). After 8 dou-
blings, SILAC (stable isotope labeling with amino acids in cell
culture) incorporation rate was determined as previously
described (21). Forward and reverse experiments were per-
formed to discard labeling biases.
Cells were lysed in RIPA buffer and proteins were measured
using the two-dimensional Quant kit (GE Healthcare, Little
Chalfont, UK). Samples (15 !g of protein) from each condition
were mixed in a 1:1 ratio and separated by SDS-PAGE. Gels
were then stained with Novex" Colloidal Coomassie Blue
Staining Kit (Thermo Fisher Scientific) and lanes were sliced
into 15 fractions and in-gel digested with trypsin (Sequencing
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grade, Promega) (22). After digestion, samples were desalted
using ZipTip C18 with 0.6 !l of resin (Millipore), dried, and
resuspended in 6 !l of 0.1% trifluoroacetic acid, 2% acetonitrile.
Mass Spectrometry and Data Analyses—We used a nanoEasy
HPLC (Proxeon, Thermo Fisher Scientific) directly coupled to a
nanoelectrospay ion source (Proxeon, ThermoFisher Scien-
tific). Peptides were trapped in a C18-A1 ASY-Column 2-cm
precolumn (ThermoFisher Scientific), eluted to a Biosphere
C18 column (C18, inner diameter 75 !m, 10 cm long, 3 !m
particle size) (NanoSeparations) and separated using a 180-min
gradient from 0 –35% buffer B (buffer A: 0.1% formic acid, 2%
ACN; buffer B: 0.1% formic acid in ACN) at a flow rate of 250
nl/min. Mass spectra were acquired in a linear ion trap Orbitrap
Velos (ThermoFisher Scientific) in the positive-ion mode. MS
survey scans (m/z 400 –1200) were acquired in the Orbitrap at a
resolution of 60,000 (FWHM) and a target value of 1.0e$06
ions. The 15 most intense ions of the survey scan were selected
for collision-induced dissociation fragmentation in the linear
ion trap, where collision energy was set to 35%. Dynamic exclu-
sion was enabled with one repeat count and exclusion dura-
tion of 30 s. Precursor ion charge state screening and mono-
isotopic precursor selection were enabled and singly charged
FIGURE 1. Cystatin D partially localizes within the cell nucleus. A, confocal immunofluorescence analysis showing that cystatin D is distributed in both
nucleus and cytoplasm of SW480-ADH cells (upper panels, scale bar, 5 !m). Nuclear staining using DAPI is shown. Preincubation of the anti-cystatin D antibody
with a specific blocking peptide and incubation with the secondary antibody alone were performed as controls. B, Western blot analysis showing the presence
of cystatin D in both cytoplasm (C) and nuclear (N) fractions of mock- and CST5-transfected SW480-ADH and HCT116 cells. For control of the purity of cellular
fractions the filters were reprobed with antibodies against "-tubulin and HDAC1.
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ions and unassigned charge states were rejected. Mass spec-
tra were searched using MASCOT (version 2.3, Matrix Sci-
ence) through Proteome Discoverer (version 1.3.0.339,
ThermoFisher Scientific) against the human SwissProt data-
base (SwissProt_57.15.fasta). Precursor and fragment mass tol-
erance were set to 10 ppm and 0.8 Da, respectively, with a
maximum of two missed cleavages for trypsin. Carbamidometh-
ylation of cysteines was set as fixed modification, and variable
modifications included oxidation of methionine, N-terminal
acetylation, and [13C]Arg, [13C]Lys. Identifications were vali-
dated using Percolator with a q-value threshold of 0.01 and
proteins were quantified using Proteome Discoverer. Data were
finally normalized using the 5% trimmed means.
Human Protein Cytokine Array—HCT116-CST5 clone 9 and
HCT116-Mock cells were cultured at 37 °C in an atmosphere of
5% CO2 for 24 h in serum-free DMEM. Conditioned media
from cultured cells were harvested and centrifuged at 1,000 ! g
to remove cell debris and filtered through 0.22 !m. Human
Cytokine Array V membranes (RayBiotech, Norcross, GA)
were blocked in blocking buffer for 1 h and then incubated with
2 ml of conditioned medium from each cell culture overnight at
4 °C. Membranes were then treated and analyzed according to
the manufacturer’s instructions (23).
Enzyme-linked ImmunoSorbent Assay (ELISA)—The levels of
CX3CL1/fractalkine in HCT116-CST5, HCT116-Mock,
HCT116-shCST5, and HCT116-shMock cell supernatants
were measured by using an ELISA kit (EHCX3CL1, Thermo-
Fisher Scientific) following the manufacturer’s instructions.
Briefly, cells were cultured and supernatants were collected
after 24 and 48 h (HCT116-CST5 and HCT116-Mock cells) or
48 h (HCT116-shCST5 and HCT116-shMock cells). Condi-
tioned media were then harvested and concentrated by means
of centrifugal filter devices (Amicon" Ultra-4 3K, Merck Milli-
pore). Standards or culture sample supernatants (100 !l) were
added in duplicate and incubated at room temperature over-
night. After four washes in 1! wash buffer, 100 !l of biotiny-
lated antibody were added to each well for 1 h. Following incu-
bation and washes, 100 !l of prepared strepavidin-HRP
solution was added to each well for 45 min. TMB substrate (100
!l) was then added to each well for 30 min at room tempera-
ture. To stop the reaction 50 !l of stop solution was added to
each well. Absorbance was measured on an ELISA plate reader
set at 450 and 550 nm.
Statistical Analysis—Results are expressed as mean ' S.E.
unless otherwise specified. Statistical significance was assessed
by two-tailed t-tests assuming equal variances. Differences
were considered significant when p % 0.05. The single asterisk
indicates p % 0.05, the double asterisk p % 0.01, and the triple
asterisk p % 0.001. All statistical analyses were performed using
the Prism software V6 (GraphPad software).
Results
Cystatin D Partially Localizes in the Cell Nucleus—To exam-
ine the intracellular localization of cystatin D in human colon
carcinoma cells we first used immunofluorescence and confo-
cal microscopy analysis. Signal of endogenous cystatin D in
SW480-ADH cells was predominantly detected in the cyto-
plasm and was also consistent within the nucleus excluding the
nucleoli (Fig. 1A). The same pattern and stronger signal was
found in cells expressing an exogenous CST5 gene (SW480-
ADH-CST5). Signal specificity was checked by preincubation
of the anti-cystatin D antibody with a blocking peptide and by
incubation with secondary antibody alone (Fig. 1A). Similar
results were found in the case of HCT116 cells that express very
low levels of nuclear cystatin D when stably transfected with an
exogenous CST5 gene (Fig. 2).
To further confirm this cellular distribution of cystatin D
protein, we performed Western blot analyses of nuclear and
cytoplasmic fractions of SW480-ADH and HCT116 cells.
Purity of fractions was checked using antibodies against
HDAC1 and "-tubulin, respectively. In agreement with data
obtained in the immunofluorescence studies, cystatin D was
detected in both cellular fractions (Fig. 1B). Taking into consid-
eration cell fractioning, dilutions, and loading, nuclear cystatin
D accounted for (10% of the total in the SW480-ADH cells and
15% in HCT116 cells.
FIGURE 2. Exogenous cystatin D partially localizes within the nucleus of HCT116 cells. Confocal immunofluorescence analysis showing that cystatin D is
distributed in both the nucleus and cytoplasm of HCT116-CST5 cells that express exogenous cystatin D (scale bars, 5 !m).
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Cystatin D Is Present at Transcriptionally Active Chro-
matin—To determine the localization of cystatin D in the cell
nucleus, we performed double immunofluorescence analyses of
cystatin D and markers of nucleolus (fibrillarin), chromatin
(pan-histone), and nuclear speckles and Cajal bodies, reservoirs
of splicing factors (TMG-cap). The lack of colocalization with
fibrillarin confirmed that cystatin D was absent from nucleoli
(Fig. 3A, upper panels). Cystatin D was distributed in nuclear
domains immunoreactive for pan-histone (Fig. 3A, middle pan-
els), whereas it was not detected, or very weak, in nuclear speck-
les and Cajal bodies (brilliant fluorescent spots) immunola-
beled with the anti-TMG-cap antibody (Fig. 3A, lower panels).
The wide distribution of cystatin D was suggestive of chromatin
localization; however, the very strong signal obtained using the
FIGURE 3. Intranuclear location of cystatin D in SW480-ADH cells. A, double immunolabeling for cystatin D in combination with fibrillarin (nucleolus marker,
upper panel), pan-histone (chromatin marker, middle panels), and TMG-cap (nuclear speckles and Cajal bodies marker, lower panels). Scale bar, 5 !m. B, upper
panels, double immunolabeling for cystatin D and histone H3K36me3, epigenetic marker of transcriptionally active chromatin. The enlarged insets show a
representative example of a nuclear domain with co-localization foci of both immunostaining signals. The graph shows a line profile analysis of signal
intensities (arbitrary units) from histone H3K36me3 (red) and cystatin D (green) across a line. Lower panels, double immunostaining analysis of cystatin D and
active RNA pol II expression. The enlarged inset shows a magnification of a representative nuclear domain illustrating the concentration of both fluorescent
signals in microfoci. The graph shows an intensity profile of cystatin D (red) and RNA pol II (green) across a line revealing the co-localization of active RNA pol
II and cystatin D in a nuclear microfocus (arrow), whereas the latter was absent from other RNA pol II-positive microfoci. Scale bars, 2.5 !m.
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anti-pan-Histone antibody precluded a definitive conclusion.
So we then performed double immunofluorescence using anti-
bodies against histone H3 trimethylated at position Lys36
(H3K36me3), an epigenetic marker of active chromatin. These
assays and their corresponding line profile analyses of fluores-
cence intensities from histone H3K36me3 (red) and cystatin D
(green) across a cell revealed a nearly total colocalization in the
graph peaks corresponding to chromatin domains (Fig. 3B,
upper panels). This result supported the presence of cystatin D
at sites of active transcription. This was confirmed by using an
antibody against the largest subunit (Rpb1) phosphorylated on
Ser2 of the heptapeptide repeat of RNA polymerase (pol) II.
Double immunofluorescence showed that cystatin D accumu-
lated and colocalized with active RNA polymerase II at specific
sites, whereas it was absent from other areas of active transcrip-
tion (Fig. 3B, lower panels). Thus, fluorescence intensity pro-
files of cystatin D (red) and RNA pol II (green) measured across
a line illustrated the co-localization of active RNA pol II and
cystatin D in a nuclear microfocus (arrow), whereas the latter
protein was absent in another microfoci immunoreactive for
RNA pol II (green peak) (Fig. 3B, lower right panel).
Immunogold electron microscopy further confirmed the
presence of cystatin D in transcriptionally active chromatin.
Thus, immunogold particles were exclusively localized in
euchromatic domains showing some microfoci of accumula-
tion, but they were totally absent from heterochromatin (Fig. 4).
Double immunogold labeling also confirmed that RNA pol II
colocalized with some cystatin D-positive nuclear microfoci
(Fig. 4, inset). However, a direct interaction between cystatin D
and RNA pol II could not be revealed by co-immunoprecipita-
tion experiments (not shown). To search for other nuclear pro-
teins interacting with cystatin D we then performed yeast two-
hybrid assays (ULTImate Y2HTM Analysis, Hybrigenics, Paris,
France). This study rendered two preferential candidates,
N-Myc interacting protein (NMI)-1 (NMI) and Cullin-1
(CUL1). However, neither were validated in co-immunopre-
cipitation or double immunofluorescence assays in HCT116
cells (not shown), suggesting that their interaction with cystatin
FIGURE 4. Immunogold electron microscopy location of cystatin D in the nuclei of SW480-ADH cells. Gold particles appear distributed in euchromatin
domains, whereas condensed chromatin areas (asterisks) are devoid of labeling. Inset, double immunogold labeling revealed the colocalization of RNA pol II
(15-nm particle) and cystatin D (10-nm particles) in a nuclear microfocus within euchromatin. Scale bars, 100 nm; inset, 50 nm.
FIGURE 5. Analysis of histone H3 expression in HCT116-CST5 and HCT116-Mock cells. Partially proteolyzed histone H3 is indicated with an
asterisk.
Nuclear Action of Cystatin D
OCTOBER 30, 2015 • VOLUME 290 • NUMBER 44 JOURNAL OF BIOLOGICAL CHEMISTRY 26539
 at Centro N
acional de Investigaciones O









Nuclear Action of Cystatin D
26540 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290 • NUMBER 44 • OCTOBER 30, 2015
 at Centro N
acional de Investigaciones O









D is either weak and/or transient, or does not take place in
human cells.
In the search for functions of cystatin D in the nucleus, we
examined its effect on the reported partial proteolysis of his-
tone H3 by cathepsin L, one of its extranuclear targets. To this
end, we analyzed in Western blots the integrity of histone H3 in
HCT116-CST5 and HCT116-Mock cells. No consistent differ-
ences were found in a series of eight independent experiments,
which showed increased, reduced, or absent histone H3 prote-
olysis in cells containing nuclear cystatin D (Fig. 5). Taken
together, these results indicate that nuclear cystatin D locates in
euchromatin at sites of active transcription and that its action
may be independent of protease inhibition.
Cystatin D Changes the Transcriptome of Human Colon Car-
cinoma Cells—To examine how this precise nuclear localiza-
tion of cystatin D at transcriptionally active sites might affect
gene expression, we compared the transcriptome of HCT116
cells lacking (HCT116-Untransfected and HCT116-Mock) and
expressing (HCT116-CST5 clones 9 and 20) cystatin D using
genome-wide expression microarrays. Cystatin D altered the
pattern of gene expression in HCT116 cells affecting up to 69
genes, of which 23 genes (33%) were induced and 46 genes
(66%) were repressed (Fig. 6) (GEO accession: GSE45904). The
majority (75%) of target genes can be classified into five func-
tional categories: cell adhesion, cytoskeleton and extracellular
matrix, transcription, signal transduction, metabolism, and
channels and transporters (Fig. 6B). The main functions
assigned to the genes affected by cystatin D were corroborated
by an enrichment analysis done using the DAVID functional
annotation tool (Table 1) (24). This analysis revealed a clear
enrichment in the functions shown in Fig. 6B that are related to
cancer regulation: regulation of apoptosis and cell death, regu-
lation of transcription and cell adhesion, cell motion and cell
migration (supplemental Table S1).
Effects of Cystatin D on the Nuclear Proteome—We next stud-
ied the effect of cystatin D on the nuclear proteome. To this
end, HTC116-CST5 and HTC116-Mock cells were cultured for
metabolic SILAC. A schematic workflow is shown in Fig. 7A. A
total of 30,879 peptides resulting in 4,337 proteins were identi-
fied. From there, 26,701 peptides were quantified, resulting in
3,995 proteins. Protein ratios were normalized using a 5%
trimmed means to correct any bias due to sample manipulation.
Proteins with fold-change &1.5 and variability %20% were con-
sidered differentially expressed. In some cases, proteins with
variability greater than 20% were manually inspected. Finally, a
total of 292 proteins were found differentially expressed. In
concordance with transcriptomic data, 80 (27%) proteins were
found up-regulated and 212 (73%) down-regulated (supple-
mental Table S2).
Using Ingenuity Pathway Analysis, we determined pathways
and biological functions affected by expression of cystatin D in
HTC116 cells. “RNA post-transcriptional modification” (n )
30) and p values ranging from 3.73E-15 to 2.89E-02, “protein
synthesis” (n ) 27), p values ranging from 2.03E-06 to 2.89E-02,
and “DNA replication, recombination and repair” (n ) 26), p
values ranging from 3.91E-06 to 2.89E-02, where the molecular
and cellular functions were most strongly associated with the
presence of cystatin D. As for canonical pathways, “assembly of
RNA-polymerase II complex” and “RhoA signaling” were the
most significant (Fig. 7B). This is consistent with the localiza-
tion of cystatin D at the sites of active transcription (Fig. 3) and
with its effects on cell adhesion (5). Finally, one of the most
significantly associated network functions was “RNA post-
transcription modification, RNA damage and repair” (score: 58;
Fig. 7C). By analyzing up and down-regulated proteins sepa-
rately, one of the most significant canonical pathways was
“cleavage and polyadenylation of pre-mRNA” and the most rel-
evant associated network was “RNA post-transcriptional mod-
FIGURE 6. Cystatin D modulates gene expression in HCT116 cells. A, heat map representation of significantly modulated genes by cystatin D: 23 up-regu-
lated genes and 46 down-regulated genes. B, functional distribution of candidate target genes regulated by cystatin D overexpression. The most represented
categories and the percentage of genes in them are shown.
TABLE 1
Functional enrichment analysis of cystatin D-regulated genes
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ification” (score 72) (Fig. 8). In agreement with transcriptomic
data and with the effect of ectopic cystatin D on the HCT116
cell phenotype, there is a clear down-regulation of genes/pro-
teins associated to cellular assembly, cytoskeleton and cell
adhesion, as well as genes/proteins implicated in cell prolifera-
tion (Figs. 7B, 7D).
Correlation between Transcriptomic and Proteomic
Data—The comparative analysis of the transcriptomic and
proteomic data revealed a good functional overlapping
between both datasets. Although few single specific genes
and proteins identified in the two studies were the same, in
part because only the nuclear proteome was studied (given
the nuclear location of cystatin D), the functional enrich-
ment analysis showed a strong agreement in terms of altered
biological functions. Thus, the most abundant function in
the genes expression signal was cell adhesion, cell junction,
cytoskeleton (22%, Fig. 6B), which was significantly repre-
sented in the proteomic data by the top proteins identified,
FIGURE 7. Effect of cystatin D on the nuclear proteome of HCT116 cells. A, scheme of the workflow followed in the quantitative proteomics analysis.
B, canonical pathways most affected by the expression of cystatin D in HTC116 cells. Yellow dots represent the ratio of the number of molecules
quantified in the SILAC analysis in the pathway relative to the total number of molecules in the pathway. Yellow line represents the threshold value from
which data are statistically significant. Nine of the most significantly affected pathways are shown. C, RNA post-transcription modification, RNA damage
and repair associated network function. This network, identified with a score of 58, shows the multiple interactions between the differentially expressed
proteins due to the presence of cystatin D and proteins in IPA database. Thirty-one proteins (26 up-regulated and 5 down-regulated) of a total of 292
were used to build this network. Holo-RNA polymerase II, CBP-p300/CREBBP-EP300, PI3K (complex), and Rnr were added to complete the network. D,
molecular and cellular functions were affected by cystatin D expression. Cellular assembly and organization is one of the functions most affected (p
value ranging from 1.71E-04 to 3.71E-02); proliferation of cells (p value 2.87E-04; z-score: #2.102 (decreased)), function related to cell growth and
proliferation was also highly affected.
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e.g. IQGAP, MAP1S, MAP1B, PLEKHF2, FSD1, and ANXA6
(Table 2). These proteins revealed significant enrichment in
functional terms like GO:0030054 cell junction and
GO:0015629 actin cytoskeleton (Table 2). Moreover, the sec-
ond most represented function in the genes changed was
transcription (14%, Fig. 6B), and this functional annotation
was also enriched in the top list of proteins derived from the
proteomic analysis: GO:0000288 nuclear-transcribed RNA,
GO:0000932 cytoplasmic RNA processing, KEGG:03013 RNA
transport. The functional enrichment analyses of the pro-
teins obtained in the proteomic analysis were done using the
tool GeneTerm-Linker (25).
Validation of Cystatin D Target RNAs and Proteins—First, we
used qRT-PCR to validate several genes identified as targets of
cystatin D in the transcriptomic study. In agreement with this,
the RNA levels of MAL2, MEF2C, AP1M2, ID3, and RUNX2
were found to be higher in two clones (clone 9 and 20) of
HCT116-CST5 cells than in HCT116-Mock cells, whereas
those of NAV3, NT5E, VCAN, WNT16, ANX3, EMP3, and
RUNX1 showed the opposite pattern of expression (Fig. 9A). Sec-
ond, Western blotting was used to validate the regulation of a sub-
set of these genes at the protein level and also of selected proteins
identified in the quantitative proteomic analysis as regulated by
cystatin D. In this way, we confirmed the up-regulation of RUNX2
and the down-regulation of RUNX1 and NR3C1, which encodes
the glucocorticoid receptor, at the protein level (Fig. 9B). In addi-
tion, we confirmed the up-regulation of IQGAP2, a regulator of
several Rho family GTPases, and the down-regulation of CBP/
CREBBP, a transcriptional regulator, as identified in the proteomic
study (Fig. 9B). As control, we analyzed the protein expression of
cystatin D and the transcriptional repressor ZEB1, an inducer of
epithelial-mesenchymal transition that is down-regulated at the
RNA level in HCT116-CST5 cells (5).
Cystatin D Changes the Pattern of Cytokine Secretion—We
examined the effect of cystatin D on cytokine secretion by colon
carcinoma cells. To this end, conditioned media from HCT116-
CST5 and HCT116-Mock cells were incubated with human
cytokine arrays containing antibodies against 79 cytokines (see
Fig. 10 for a map of the localization of cytokines in the arrays).
Only those cytokines showing the same expression in two bio-
logical replicate assays with a cut-off of 1.2-fold change were
considered affected by the treatment (Fig. 11A). HCT116-CST5
cells showed reduced secretion (0.76 – 0.63-fold) of fibroblast
growth factor-4, CX3CL1/fractalkine, neurotrophin 4/NT-4,
oncostatin-M, pulmonary and activation-regulated chemo-
kine/CCL18 and transforming growth factor B3/TGF-"3 as
compared with HCT116-Mock cells (Fig. 11B). The reduction
of CX3CL1/fractalkine secretion was further confirmed by
means of ELISA (around 5-fold) (Fig. 11C).
Effects of Silencing Endogenous Cystatin D—Finally, to con-
firm that endogenous cystatin D has the properties of an
authentic transcriptional regulatory protein we knocked
down CST5 by stable shRNA expression. CST5 down-regu-
lation was confirmed in two clones, sh19 and sh20, by qRT-
PCR analysis (Fig. 12A). To investigate putative effects of
CST5 down-regulation on the expression of the genes iden-
tified as targets of cystatin D in the transcriptomic analysis,
we performed several qPCRs. Opposite to what happened
upon CST5 overexpression (Fig. 9A), the RNA levels of
MEF2C and ID3 were lower and those of RUNX1, ANX3,
VCAN, NT5E, and WNT16 were higher in clones sh19 and
sh20 than in HCT116-shMock cells (Fig. 12B). AP1M2 and
FIGURE 8. STRING protein interaction analysis. Proteins down- and up-regulated by cystatin D were analyzed for protein interactions using STRING. Proteins
were clustered setting the MCL algorithm to 2. A, down-regulated proteins. B, up-regulated proteins. Colored lines represent interaction partners retrieved from
different prediction methods: neighborhood, dark green; gene fusion, red; Co-occurrence, dark blue; co-expression, black; experiments, pink; databases, light
blue; text mining, light green.
TABLE 2
Functional enrichment analysis of the top 80 cystatin-up-regulated proteins
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EMP3 genes were unaffected by CST5 down-regulation,
indicating that their expression depends also on additional
factors that compensate the reduction of cystatin D level.
Additionally, we examined the effect of CST5 down-regula-
tion of the secretion of CXC3CL1/fractalkine. In line with
results found for most target genes and in contrast to the
effect of CST5 overexpression (Fig. 11C), clones sh19 and
sh20 secreted higher amounts of this chemokine than
shMock cells. Altogether, these results reinforce the idea
that cystatin D has a previously unpredicted gene regulatory
action.
Discussion
In this study, we examined the function of cystatin D in
human colon carcinoma cells. We had previously reported that
cystatin D exerts biological effects that are somehow unex-
FIGURE 9. Validation of cystatin D targets. A, qRT-PCR analysis of the expression level of several RNAs identified as candidate targets of cystatin D in
the transcriptomic study. Expression levels in two clones (9 and 20) of HCT116-CST5 cells were normalized versus those in HCT116-Mock cells. Data are
presented as mean ' S.E. of at least two independent experiments. B, Western blot analysis (20 !g of total cell extracts) of the expression in HCT116-
CST5 and HCT116-Mock cells of several proteins selected from the transcriptomic or proteomic analyses. Cystatin D and loading controls (lamin B,
"-tubulin) are also shown.
FIGURE 10. Scheme indicating the position of the cytokines tested in the array.
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pected for a mere protease inhibitor, such as the repression of
c-MYC and the cell cycle or the increase of intercellular adhe-
sion (5). Now, we show that a proportion of endogenous cysta-
tin D protein in SW480-ADH cells, as well as of that ectopically
expressed in HCT116 cells, locates within the cell nucleus. Evi-
dence is provided that nuclear cystatin D is present at specific
sites of defined transcriptionally active euchromatin (26). This
indicates that cystatin D is not a constitutive structural compo-
nent of chromatin or the general transcription machinery but,
instead, is involved in the expression of a particular set of genes.
Consistently, transcriptomic data have revealed that cystatin D
does not change the global transcription rate in the cell but
alters the expression of specific genes. These target genes pref-
erentially affect a number of biochemical routes and cellular
functions such as cell adhesion, transcription, signal transduc-
tion, or metabolism. An additional proteomic analysis of
nuclear extracts confirmed that the levels of several proteins
with roles in RNA biology, including the key transcription reg-
ulator CBP/CREBBP, are modulated by cystatin D. In addition
to transcriptional regulation, the localization of cystatin D in
euchromatin is consistent with the proteome data on the most
relevant nuclear functions affected by expression of cystatin D.
These include pre-mRNA processing, a nuclear function that
preferentially occurs co-transcriptionally in euchromatin
domains (27). Although the transcriptomic and proteomic
analyses do not match in the same genes/proteins, they point to
a robust phenotypic effect of cystatin D regulating cell adhe-
sion, cytoskeleton and RNA synthesis, and processing. In sum-
mary, our study identifies a novel role of cystatin D as a specific
modulator of gene expression in the nucleus.
Our attempts to identify cystatin D binding partners did not
validate the strong interaction with NMI-1 and Cullin-1 found in
yeast two-hybrid assays nor did they reveal specific binding to his-
tone H3. This suggests that cystatin D action at the chromatin level
relies on weak and/or transient, dynamic interactions most prob-
ably with one or more components of RNA synthesis-modifica-
tion complexes. The study of the putative interaction of cystatin D
with human cathepsin V, a close homologue of cathepsin L that is
not found in mice, seems of especial interest giving that cathepsin
V, but not cathepsin L, binds DNA and DNA modulates the inhi-
bition of cathepsin V by MENT (28).
Our data demonstrate that cystatin D alters the expression of
several genes that may contribute to its previously described
tumor suppressor activity and may also partially mediate the
antitumor activity of 1,25-(OH)2D3. One of these genes is
CX3CL1/fractalkine, which encodes a chemokine with pro-in-
flammatory and pro-tumorigenic activity in several types of
cancer (29 –31). The repressive effect of cystatin D on the secre-
tion of CX3CL1/fractalkine in our system supports a tumor
suppressive action. This is further suggested by the inhibition of
FGF-4, which has strong mitogenic, promigratory, and invasive
activity (32, 33) and oncostatin-M, a proinflammatory and pro-
metastatic cytokine (34). Two other genes whose expression is
(differentially) affected by cystatin D are RUNX1 and RUNX2,
which together with RUNX3 are members of a family of tran-
scription factors that regulate a wide range of biological pro-
cesses and have context-specific roles in carcinogenesis (35,
36). Mutations in RUNX1, which are down-regulated by cysta-
tin D, are associated with some leukemias and breast and
esophagous carcinomas, whereas this gene has also been
reported to act as tumor suppressor in T-ALL (36). RUNX1 has
recently been shown to stimulate STAT3 signaling and has
been implicated in several epithelial cancers (37). Notably,
genetic variations of RUNX1 and RUNX2 genes associate with
the risk of colon and rectal cancer (38).
Interestingly, cystatin D down-regulates the VCAN gene
encoding versican, which is associated with colon cancer pro-
gression (39). NAV3, a gene that is aberrantly expressed in
colon cancer linked to inflammation and cell proliferation (40),
is also repressed by cystatin D. Likewise, we found that cystatin
D-expressing cells contain lower RNA levels of WNT16, an acti-
vator of "-catenin transcriptional activity and cell proliferation,
and of NT5E, which encodes ecto-5"-nucleotidase (CD73) and
FIGURE 11. Modulation of cytokine secretion by cystatin D. A, hybridiza-
tion of cytokine antibody arrays with conditioned media from HCT116-CST5
and HCT116-Mock cells. Two independent biological samples using equal
amounts of conditioned media of the two cell types were used. B, quantifica-
tion of the down-regulation of six cytokines by cystatin D (mean ' S.E., arbi-
trary units) obtained using two independent biological samples. C, down-
regulation of CX3CL1/fractalkine by cystatin D as shown by a specific ELISA.
Data are presented as mean ' S.E. of three independent experiments.
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whose high expression is proposed as an independent bio-
marker of poor survival of colorectal cancer patients (41).
How cystatin D protein that lacks a conventional nuclear
localization signal enters into the cell nucleus is unclear. One
possibility is that cystatin D (15 kDa) may enter the nucleus by
passive diffusion as proposed for those proteins of molecular
mass up to 40 kDa (42). Alternatively, it may be imported by
interaction with other proteins that contain a functional
nuclear localization signal (43).
In conclusion, our results demonstrate that cystatin D is a mul-
tifaceted protein with a previously unpredicted activity in the cell
nucleus modulating the expression of specific genes, some of
which are involved in key cellular functions, the control of the
epithelial adhesive phenotype or encoding tumor-related cyto-
kines. This activity of the fraction (around 10%) of cystatin D mol-
ecules present within the cell nucleus is unrelated to the protease
inhibitory function of the more abundant (90%) extranuclear frac-
tion and may contribute to its tumor suppressor activity and to the
protective action of 1,25-(OH)2D3 in colon cancer.
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Casal, J. I. (2012) High expression of IL-13 receptor #2 in colorectal cancer
is associated with invasion, liver metastasis, and poor prognosis. Cancer
Res. 72, 2780 –2790
24. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009) Systematic and
integrative analysis of large gene lists using DAVID bioinformatics re-
sources. Nat. Protocols 4, 44 –57
25. Fontanillo, C., Nogales-Cadenas, R., Pascual-Montano, A., and De las Ri-
vas, J. (2011) Functional analysis beyond enrichment: non-redundant re-
ciprocal linkage of genes and biological terms. PloS One 6, e24289
26. Carmo-Fonseca, M. (2002) The contribution of nuclear compartmental-
ization to gene regulation. Cell 108, 513–521
27. Moore, M. J., and Proudfoot, N. J. (2009) Pre-mRNA processing reaches
back to transcription and ahead to translation. Cell 136, 688 –700
28. Ong, P. C., McGowan, S., Pearce, M. C., Irving, J. A., Kan, W. T., Grigoryev,
S. A., Turk, B., Silverman, G. A., Brix, K., Bottomley, S. P., Whisstock, J. C.,
and Pike, R. N. (2007) DNA accelerates the inhibition of human cathepsin
V by serpins. J. Biol. Chem. 282, 36980 –36986
29. Xu, X., Wang, Y., Chen, J., Ma, H., Shao, Z., Chen, H., and Jin, G. (2012)
High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of
pancreatic ductal adenocarcinoma. J. Gastrointest. Surg. 16, 1493–1498
30. Corcione, A., Ferretti, E., and Pistoia, V. (2012) CX3CL1/fractalkine is a
novel regulator of normal and malignant human B cell function. J. Leukoc.
Biol. 92, 51–58
31. Kim, M., Rooper, L., Xie, J., Kajdacsy-Balla, A. A., and Barbolina, M. V.
(2012) Fractalkine receptor CX3CR1 is expressed in epithelial ovarian car-
cinoma cells and required for motility and adhesion to peritoneal meso-
thelial cells. Mol. Cancer Res. 10, 11–24
32. Kosaka, N., Sakamoto, H., Terada, M., and Ochiya, T. (2009) Pleiotropic
function of FGF-4: its role in development and stem cells. Dev. Dyn. 238,
265–276
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